Shelly S. Lo

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection

Shelly S. Lo, Patricia Mumby, John D. Norton et al. · Journal of Clinical Oncology · 2010 · 303 citations · Full text

Medicine, Oncology, Breast Oncology +16

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

Douglas Yee, Angela DeMichele, Christina Yau et al. · JAMA Oncology · 2020 · 225 citations · Full text

Medicine, Oncology, Breast Oncology +15

Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.

Peter Grudzien, Shelly S. Lo, Kathy S. Albain et al. · PubMed · 2010 · 142 citations

Life Sciences, Cell Biology, Oncology +17

Neoadjuvant Imatinib in Gastrointestinal Stromal Tumor of the Rectum: Report of a Case

Shelly S. Lo, Georgios I. Papachristou, Sydney Finkelstein et al. · Diseases of the Colon & Rectum · 2005 · 51 citations

Medicine, Oncology, Surgery +17